1. Home
  2. |Insights
  3. |IoT Goes Federal under Newly Signed Law

IoT Goes Federal under Newly Signed Law

Client Alert | 1 min read | 12.10.20

Last week, the President signed the Internet of Things (IoT) Cybersecurity Improvement Act into law, kicking off a multi-year process that will culminate in the first-ever federal requirements for IoT devices. Under the law, the National Institute of Standards & Technology (NIST) is now charged with drafting and finalizing security requirements for IoT devices, as well as guidelines for managing disclosures about those devices’ security vulnerabilities. In two short years, the federal government will then be prohibited from procuring IoT devices unless (1) the devices meet the pending NIST requirements; or (2) the devices are granted a formal waiver by an agency Chief Information Officer. In addition to creating yet another cybersecurity regime for the government contracting community, the law will create a new benchmark for consumer-facing companies to consider when assessing and complying with the growing number of states imposing their own “reasonable security” requirements for IoT devices.

Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...